Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the first patient in Japan has been treated with AnaConDa and that the registration work for IsoConDa in Japan has been initiated. The Japanese market potential is estimated at EUR 300 million annually.
At the Shiga University Hospital, Shiga University of Medical Science Hospital, SUMS, the first patient has now clinically been treated with AnaConDa.
“The first patient in Japan is of course a milestone, but in addition, the AnaConDa treatment is currently being evaluated by the ethical committees of five university
Source: Progress in Japan